Aug 21, 2026 07:04AM
May 20, 2026 06:49AM
Mar 23, 2026 06:48AM
Mar 18, 2026 05:31PM
Nov 14, 2025 07:00AM
Oct 6, 2025 07:45AM
Oct 6, 2025 07:30AM Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
May 19, 2025 08:00AM
Dec 17, 2024 07:01AM
Dec 17, 2024 07:00AM
Dec 17, 2024 07:00AM
Aug 14, 2024 04:30PM
May 15, 2024 04:15PM
Apr 30, 2024 06:46AM Ladenburg Thalmann Starts Marker Therapeutics (MRKR) at Buy
Mar 25, 2024 05:45PM
Jan 8, 2024 08:25AM
Jan 8, 2024 08:24AM
Dec 21, 2023 11:00AM
Dec 11, 2023 07:05AM
Dec 11, 2023 07:00AM
Nov 9, 2023 05:00PM Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Aug 14, 2023 04:30PM
Aug 7, 2023 07:13AM
Aug 7, 2023 07:00AM
Jul 10, 2023 07:02AM
Jul 10, 2023 07:00AM
Jun 26, 2023 07:10AM
Jun 26, 2023 07:00AM Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
May 31, 2023 06:34AM
May 31, 2023 06:30AM
May 1, 2023 07:31AM
May 1, 2023 07:30AM
Mar 22, 2023 08:10AM
Nov 22, 2022 07:04AM
Nov 22, 2022 07:00AM Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
Nov 10, 2022 04:05PM
Sep 13, 2022 07:02AM
Sep 13, 2022 07:00AM
Aug 11, 2022 04:22PM
Aug 4, 2022 04:39PM
Aug 4, 2022 04:37PM
Jun 23, 2022 09:00AM IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
Apr 26, 2022 07:00AM
Mar 18, 2022 05:57AM
Mar 17, 2022 05:45PM
Feb 16, 2022 04:31PM
Feb 16, 2022 04:30PM
Jan 19, 2022 04:50PM
Jan 19, 2022 04:49PM Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
Aug 19, 2021 04:20PM

330,538 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All